J&J Signals Exit from Less Profitable Orthopedic Markets

2023-10-18

并购

Johnson & Johnson plans to exit "less profitable" markets and product lines across its orthopedics by the end of 2025, CFO Joe Wolk said during the company's third-quarter earnings call Tuesday.

Wolk said this exit would cause some short-term revenue disruption in orthopedics of about $250 million total over the next two years. On the plus side, he expects these actions to improve J&J's ability to meet demand, resulting in accelerated growth and enhanced profitability. Total costs associated with this restructuring program are estimated to be between $700 million and $800 million, Wolk noted.

"We are on a journey of improvement in orthopedics," Joaquin Duato said, according to a SeekingAlpha transcript of the call. "We want to be number one and number two in every segment we compete. And that is a place where we are not there yet, but we are very confident that we are going to continue to make improvements by investing and by growing in the highest growth segments."

Duato said J&J has already made some improvements in its orthopedics portfolio, such as in the areas of knee replacement and revision.

"We have a more complete portfolio now on the revision side, on the cementless side. We are launching now our Velys orthopedics total robot, total knee surgery replacement in Europe. And we already have about 30,000 procedures that have been performed with our Veyls robotic system," Duato said.

J&J's Depuy Synthes unit has won FDA clearance for its Velys robotic-assisted solution in January 2021. The device is designed for use with the Attune Total Knee System.

Velys is designed to use advanced planning capabilities and is designed to help surgeons accurately resect bones that align and position the implant relative to the soft-tissue during total knee replacement without the need for pre-operative imaging.

J&J inherited the Velys technology through its Orthotaxy acquisition in 2018. The acquisition helped J&J more effectively compete against Stryker’s Mako orthopedic surgical solution.

The CEO also said J&J is boosting its penetration in the ambulatory surgical centers, which he described as a fast-growing segment.

"Overall, in orthopedics, we are determined to continue our journey of improvement. We are focused on having the right portfolio. We have a very strong team in the field, and ... we have a plan to be able to continue to improve our margins in orthopedics.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构